CRISPR Therapeutics AG
NASDAQ:CRSP
CRISPR Therapeutics AG
NASDAQ:CRSP
Price:
53.55 USD
0.49%
Market Closed
Updated:
May 10, 2024
Section:
Relative Value
The Relative Value of one
CRSP
stock under the Base Case scenario is
158.55
USD.
Compared to the current market price of 53.55 USD,
CRISPR Therapeutics AG
is
Undervalued by 66%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CRSP
Relative Value
Base Case
158.55
USD
Undervaluation 66%
Valuation Multiples
Multiples Across Competitors
CRSP Competitors Multiples
CRISPR Therapeutics AG Competitors
CRISPR Therapeutics AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
4.3B USD | 11.5 | -27.9 | -12.8 | -11.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 5.2 | 58.8 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167.8B USD | 5.7 | 44.6 | 18.8 | 30.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108B USD | 10.9 | 29.8 | 24 | 25.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.7B USD | 8.1 | 27.7 | 22.3 | 24.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.9B AUD | 6.2 | 36.1 | 21.7 | 26.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.5B USD | 2.9 | 166.3 | 6.7 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47B USD | 9.1 | -7.9 | -8.6 | -7.6 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.4B USD | 3.4 | 27.8 | 14.2 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.6 | 45.6 | 62.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
